ICPT News and Press, Intercept Pharmaceuticals Inc. From 07/29/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...

MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2022 fi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Iryna Imago / Shutterstock.com Today, Intercept Pharmaceuticals (NASDAQ: ICPT ) disclosed data from its clinical study of a proposed treatment for patients with liver fibrosis due to nonalcoholic steatoh...

Gainers: Longeveron ( LGVN ) +16% . Adverum Biotechnologies ( ADVM ) +13% . 89bio ( ETNB ) +12% . Mainz Biomed ( MYNZ ) +11% . Shineco ( SISI ) +8% . Losers: DiaMedica Therapeutics ( DMAC ) -41% . Cytom...

The commercial stage biotech Intercept Pharmaceuticals ( NASDAQ: ICPT ) announced on Thursday that the company would resubmit a new drug application to the FDA for its NASH candidate obeticholic acid ( OCA ) after a new interim analysis in a pivotal trial indicated positiv...

OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p<0.0001), consistent with the original REGENERATE analysis OCA 25 mg demonstrated double the response rate in reduction of liver fibrosis without worsening of NAS...

MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between I...

Arrowhead Pharmaceuticals ( ARWR ), a clinical-stage biotech focused on RNA interference (RNAi) therapeutics surged on above average volume on Wednesday in solidarity with several other drug developers targeting the liver disease, non-alcoholic steatohepatitis (NASH). Despite ...

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of novel therapies to treat central nervous sys...

The most heavily shorted names have been rallying off their lows in the past several days. On a relative basis, the 100 most heavily shorted stocks versus the Russell 3,000 have broken out of the downtrend that has been in place since the height of the meme stock mania in January 2021...